Foundation For Innovative New Diagnostics Find
81% goes to programs $1 to raise $100 Declining revenue
Foundation For Innovative New Diagnostics Find is a 501(c)(3) organization, registered in 2003, with $49,306,331 in FY2024 revenue. CharityIndex grades it B+, and it directs about 81% of spending to programs.
Grandsaconnex, Switzerland, 00000 EIN 98-0407553 Since 2003
Revenue (FY2024)
$49.3M
▼ 45.6% vs prior year
Medical Research median: $217K
Expenses (FY2024)
$56.8M
Net assets
$8.6M
Employees
227
CharityIndex rating
One independent A+ to F grade from four published criteria, each scored separately from IRS filings and combined by weight.
B+
★★★★
Rated on 4 of 4 criteria.
Held down by its weakest criterion — a strong score on one criterion can't hide a weak one.
How the rating works →AProgram efficiency40% of the rating81% to programs · $1 to raise $100
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Foundation For Innovative New Diagnostics Find: 81% to programs · $1 to raise $100 earns a A on this criterion. See the exact thresholds →
C+Financial health25% of the rating2 mo reserves · -15% margin
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Foundation For Innovative New Diagnostics Find: 2 mo reserves · -15% margin earns a C+ on this criterion. See the exact thresholds →
A+Governance25% of the rating6 of 6 checks met
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Foundation For Innovative New Diagnostics Find: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
A+Transparency10% of the rating5 of 5 disclosure signals
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Foundation For Innovative New Diagnostics Find: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Mission
The development and implementation of new, low cost diagnostics for infectious diseases for use in low-resource areas.
What they do
Neglected tropical diseases (expenses $4,890,019) nt-p19-003 chagas diagnostics market sizing model nt-p16-001 hat diagnostic algorithm for south sudan nt-p18-002 intermediary field evalution report including the rdt performance against the reference standard nt-p19-003 market landscape report of diagnostic products for chagas disease nt-p18-002 report detailing the economic analysis of using the sch caa rdt instead of current diagnostic tools nt-p16-001 south sudan hat access database nt-p23-004 test directory for visceral leishmaniosis medical affairs department (expenses $4,108,156) administrative clinical activities womens health department (expenses $3,248,296) wh-p23-001 advancing self collection for hpv testing as a primary cervical cancer screening strategy in sub-saharan africa wh-p23-001 assessing feasibility and effectiveness of point-of-care limited hpv genotype tests in cervical cancer screening: a modelling study wh-p23-001 assessing feasibility and efficiency of limited hpv genotype targets in cervical cancer screening for sub-saharan africa wh-p23-001 human papillomavirus self-sampling versus provider-sampling in lmic countries wh-p24-001 technology landscape of tools for anaemia at primary health centers wh-p23-001 towards 70% cervical cancer screening coverage wh-p23-001 tpps and relevance of community engagement pandemic threats (expenses $3,232,156) pt-p24-003 chikungunya test directory pt-p22-006 diagnostic accuracy of three mpox lateral flow assays for antigen detection in the democratic republic of congo and the united kingdom pt-p22-005 dno analysis for lassa and yelloe fever in nigeria pt-p24-002 dxconnect test directory for lassa pt-p24-002 dxconnect test directory for nipah pt-p22-006 evaluation of the diagnostic accuracy and analytical sensitivity of the novel xpert mpox (cepheid) and standard m10 mpx/opx (sd biosensor) molecular point-of-care assays for the detection of mpox virus in skin lesion swabs and upper-respiratory swab sa pt-p24-001 filovirus landscape pt-p23-002 i-mcm-net mapping document pt-p24-002 lassa landscape manuscript pt-p21-001 license agreement for yellow fever ag ns1 rdt pt-p24-004 mpox test directory pt-p24-004 mpox test tracker pt-p23-002 pdxri pt-p22-007 viral hemorrhagic fever strategic plan pt-p23-002 whs roadmap for 100dm for diagnostics meeting report antimicrobial resistance (expenses $2,773,685) am-p22-002 a call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries fe-p18-003 a qualitative thematic synthesis study with a discussion of intervention design to explore drivers of adherence to prescription in four sites in india am-p21-001 affordable blood culture systems from china: in vitro evaluation for use in resource-limited settings am-p24-001 antimicrobial stewardship modules am-p23-001 assessment of antimicrobial resistance diagnostic capacity and antibiotic use in 30 health facilities in india am-p23-001 assessment of antimicrobial resistance diagnostic capacity and antibiotic use in 10 counties in kenya am-p23-001 assessment of antimicrobial resistance diagnostic capacity and antibiotic use in kenya am-p21-001 blood culture bottles remain efficient months after their expiration date: implications for low- and middle-income countries. am-p22-002 call for public consultation: target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final tpp currently in clearance) fe-p18-003 cost-effectiveness of test-and-treat strategies to reduce the antibiotic prescription rate for acute febrile illness in primary healthcare clinics in africa fe-p18-003 cost-effectiveness of test-and-treat strategies to reduce the antibiotic prescription rate for acute febrile illness in primary healthcare clinics in africa am-p22-003 development of a novel fluorescent-based lateral flow assay for the detection of neisseria gonorrhoeae at the point of care am-p22-003 evaluat
Contact & location
- Address
- Grandsaconnex, Switzerland, 00000
- City
- —
- State
- —
- Category
- Medical Research
- Subcategory
- Organ Research
- Phone
- …
- Website
- …
Financial trends
Revenue declined from $98.2M (FY2020) to $49.3M (FY2024) across 5 reported years.
Financial snapshot
Financial health & position (FY2024)
Liabilities $42.6MNet assets $8.6M
Operating margin
-15.3%
Spent more than it raised in the latest fiscal year.
Total assets
$51.3M
Total liabilities
$42.6M
Net assets
$8.6M
Salaries & benefits
$20.5M
36% of expenses
Board members
9
9 independent
Financials by year
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $49,306,331▼45.6% | $56,828,646▼40.9% | $8,640,440▼46.5% | $51,274,531▼37.0% | 990 |
| 2023 | $90,612,477▼37.2% | $96,117,239▼34.3% | $16,162,755▼25.4% | $81,417,302▼40.8% | 990 |
| 2022 | $144,248,069▲31.1% | $146,186,498▲52.9% | $21,667,517▼1.7% | $137,542,319▼27.4% | 990 |
| 2021 | $110,032,140▲12.0% | $95,593,710▲4.9% | $22,044,318▲69.8% | $189,507,117▲76.6% | 990 |
| 2020 | $98,212,578 | $91,124,840 | $12,986,212 | $107,298,970 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Leadership & compensation (FY2024)
Highest-paid: Darryl English — $342,536 (0.60% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Darryl English | Deputy Director, Finance (thru 11/24) | 40 | $342,536 |
| Marta Fernandez Suarez | Chief Technology Officer (thru 10/24) | 40 | $285,980 |
| Sergio Carmona | Chief Medical Officer (thru 9/24) | 40 | $284,240 |
| Brooke Nichols | Senior Director, Impact | 40 | $265,429 |
| Beatrice Mouton | Director, Human Resources | 40 | $260,701 |
| Morten Ruhwald | Director, Tuberculosis Programme | 40 | $244,800 |
| Shaukhat Ali Khan | Director Strategic Information | 40 | $235,091 |
| Sanjay Sarin | Vp, Access (thru 10/24) | 40 | $232,372 |
| Sharon Saacks | Senior Director, Programme Operations (thru 7/24) | 40 | $230,858 |
| Norma Torres | Chief Operating Officer (thru 5/24) | 40 | $215,973 |
| Maria Cecilia Ferreyra Arellano | Director of Amr Programme | 40 | $213,012 |
| William Rodriguez | Chief Executive Officer (thru 6/24) | 40 | $197,568 |
| Cassandra Kelly-cirino | Vp, Health Programmes (thru 8/24) | 40 | $191,471 |
| Kevin Tetteh | Director, Malaria Fever Programme | 40 | $181,958 |
| Willo Brock | Executive Vp, External Affairs (thru 6/24) | 40 | $163,705 |
| Dayo Adetifa | Chief Transformation Officer/ceo | 40 | $138,966 |
| Louisa Chaubert | Director of Finance (thru 12/23) | 0 | $95,808 |
| Ayoade Alakija | Chairman of the Board | 1 | — |
| David Heymann | Member of the Board | 1 | — |
| Frutiger Christian | Member of the Board | 1 | — |
Top vendors & contractors (FY2024)
| Contractor | Services | Paid |
|---|---|---|
| World Health Organization | Public-health Technical Support | $7,000,000 |
| Institute Pasteur of Dakar | Research and Laboratory Diagnostics | $4,537,400 |
| Airplus International | Flight Arrangment Services | $1,289,682 |
| Global Fund Global Health Campus | Office Space Provider | $742,311 |
| Interhyve Sarl | It Support Services | $601,887 |
Grants made · $1.4M in FY2024
10 grants totaling $1.4M in FY2024. All grants made by Foundation For Innovative New Diagnostics Find →
| Recipient | Purpose | Amount |
|---|---|---|
| University of North Carolina At Chapel Hill | Laboratory strengthening to support clinical care and research | $506,168 |
| Diagnostic Consulting Network | Development of diagnotic tests | $410,848 |
| Clinton Health Access Initiative Inc | To support tb elimination efforts | $288,213 |
| American Society of Tropical Medicine and Hygiene | Publication of journal supplement | $50,000 |
| Quantigen | Accelerating tools to drive tuberculosis detection | $40,570 |
| Path | Genomics trainings. supporting the africa cdc workforce development effort for pathogen genomic surveillance | $40,119 |
| Dimagi Inc | Production of mobile phone apps that collects data from rapid vitro diagnostic test and that can aid an rdt user in interpreting the test results | $30,457 |
| Georgetown University | Driving equitable access to testing in lmics through effective and affordable tests and infrastructure | $24,922 |
| Drugs & Diagnostics For Tropical Diseases | Rapid diagnostic testing for buruli ulcer | $10,011 |
| President and Fellows of Harvard College | Project agreement with harvard for seq&treat mutations catalogue work | $9,802 |
Frequently asked questions
- Is Foundation For Innovative New Diagnostics Find a legitimate nonprofit?
- Yes. Foundation For Innovative New Diagnostics Find is a 501(c)(3) organization registered with the U.S. Internal Revenue Service under EIN 98-0407553. Donations are tax-deductible.
- What is Foundation For Innovative New Diagnostics Find's EIN?
- Foundation For Innovative New Diagnostics Find's Employer Identification Number (EIN) is 98-0407553.
- How much revenue does Foundation For Innovative New Diagnostics Find report?
- Foundation For Innovative New Diagnostics Find reported $49,306,331 in total revenue on its fiscal year 2024 IRS Form 990 filing.
- How much of Foundation For Innovative New Diagnostics Find's spending goes to programs?
- Foundation For Innovative New Diagnostics Find spends about 81% of its total expenses on programs, based on its latest IRS Form 990.
- What financial grade does Foundation For Innovative New Diagnostics Find have?
- CharityIndex grades Foundation For Innovative New Diagnostics Find B+, based on program efficiency and fundraising cost.
- How much does Foundation For Innovative New Diagnostics Find's highest-paid employee make?
- The highest reported compensation on Foundation For Innovative New Diagnostics Find's latest Form 990 is $342,536, paid to Darryl English (Deputy Director, Finance (thru 11/24)).
Explore more
Data for Foundation For Innovative New Diagnostics Find (EIN 98-0407553) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.